Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Acute Promyelocytic Leukemia with t(11;17)(q23;q21); ZBTB16-RARA — Survival · CancerIndex

Cancers
Neoplasm
Neoplasm by Special Category
Malignant Neoplasm
Leukemia
Acute Leukemia
Acute Myeloid Leukemia
Acute Myeloid Leukemia with Genetic Abnormalities
Acute Promyelocytic Leukemia
Acute Promyelocytic Leukemia with a Variant RARA Rearrangement
Acute Promyelocytic Leukemia with t(11;17)(q23;q21); ZBTB16-RARA

Molecular Subtype

Acute Promyelocytic Leukemia with t(11;17)(q23;q21); ZBTB16-RARA

CI-CAN-00009322Explore in graph →

Hematologic

NCIt: C36056

Overview
Statistics
Survival
Genomics
Variants & evidence
Drugs
Trials
Research
Rankings
Sources & provenance

Survival

Population survival

Data not yet available

No survival observation is attached. Survival statistics require stage, staging system, diagnosis period, survival type and population — they are only imported with that full context (SEER, once credentials and terms are settled).

What CancerIndex knows

Statistics tab
Methodology: 5-year relative survival